This morning, the American Civil Liberties Union, which will be represented in Wednesday’s hearing on Section 101 reform by Senior Legislative Counsel Kate Ruane, announced an urgent joint phone briefing for members of Congress and staff to address the contention that the “Proposed Patent Bill Would Jeopardize Health Care and Harm Medical Research.” The phone briefing, taking place today at 2:30 pm EST, will be jointly held by representatives from the ACLU, the Association for Molecular Pathology, a breast cancer survivor and patient, My Gene Counsel, and Invitae. Below, Sherry Knowles, former Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, rebuts the arguments made in both the ACLU’s briefing announcement and associated letter to Congress on this topic.
Sherry Knowles Responds to ACLU’s Urgent Phone Briefing and Letter Opposing Reform to Section 101
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update
Recent Posts
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update